46 If a trial sequential analysis results in insignificant findings before the required information size has been reached (no Z curve crossing of the trial sequential monitoring boundaries), the conclusion should be that more trials are needed to either accept or reject the intervention effect used for calculating the required sample size.
Despite potential biases as well as heterogeneity, inconsistency, diversity, and overlapping prediction intervals, the overall quality of evidence was upgraded from low to moderate based on the magnitude of effect observed, trial sequential analysis results, and lack of adverse events.
This is especially relevant given that a low rating is based on the belief that additional evidence in the future would most likely change the direction of effect, something that the investigative team does not believe will happen, especially given the trial sequential analysis results.
In this review, in order to combine trials for analysis, results in each arm have been compared with the single placebo group, and where meta-analysis is done, numbers in the placebo group have been divided into three to avoid biasing the CIs.
As shown in table 2 and figure 2, when the database outcomes analysed with conventional biostatistical techniques differed significantly from the trial, the PERR analysis results were either not significantly different from or much more similar to the trial results.
It is now clear that the use of a 3-year time horizon in our previous within-trial economic analysis resulted in a higher cost per QALY gained than the current analysis, which used a 10-year time horizon (6).
While we did not include pediatric trials in our analysis, results from a recent systematic review assessing antifungal therapy in children with invasive fungal infections reported congruent conclusions[ 25].
Following each interim analysis, the Data Monitoring Committee made recommendations to continue, modify, or stop the trial, based on interim analysis results (stopping criteria at n1 = 60, boundary P-value = 0.00015; n2 = 40, boundary P-value = 0.00258; n3 = 100, boundary P-value = 0.02396).
In contrast to these small clinical trials, in this retrospective analysis results of more than 4,000 patients managed by the NTS using CoaguChek XS and INRatio2 with the same clinical protocol are reported.
Unfortunately, the trial ended prematurely due to interim analysis results that showed that the trial crossed the futility boundary after the 92 PFS events were analyzed.
